ARTICLE IN PRESS
AbstractHyperglycaemia in patients receiving enteral or parenteral nutrition is a major problem due to its high prevalence and possible consequences in terms of morbidity and mortality. However, the management of diabetes/stress hyperglycaemia during artificial nutrition remains largely unknown, especially in non-critically ill patients. The indications and access routes for artificial nutrition are not different in patients with diabetes/stress diabetes than in non-diabetics. We do not recommend using enteral formulas designed for patients with diabetes. The glycaemic objective must be individualized. We recommend a preprandial blood glucose levels between 100 and 140 mg/dL (5.5 and 7.8 mmol/L) and postprandial levels between 140 and 180 mg/dL (7.8 and 10 mmol/L). A frequent monitoring of capillary glycaemias is mandatory. The best drug treatment for treating hyperglycaemia/diabetes is insulin and we recommend to adapt the theoretical insulin action to the nutrition infusion regimen. The management of these patients needs the help of a multidisciplinary experimented staff.
Our experience demonstrated that the M&M procedure could be performed safely laparoscopically. The satisfactory results on weight loss, obesity-associated mordities, and quality of life will need to be confirmed on longer follow-up.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.